Drug Trial Radar · NCT03891576
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
83
Actual
Start
Nov 13, 2019
Primary completion
Aug 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- North Eastern German Society of Gynaecological Oncology
- First posted
- Mar 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates whether the adoption of the RADAR dosing strategy could further reduce treatment related toxicities improving the safety profile of niraparib.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
NiraparibDrug
Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Occurrence of grade ≥3 thrombocytopeniaTime frame: 3 months
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin
Berlin, Germany
University Hospital Dresden
Dresden, Germany
Kliniken Essen Mitte
Essen, Germany
ASST degli Spedali Civili di Brescia
Brescia, Italy
Istituto Europeo di Oncologia
Milan, Italy
Istituto Nazionale dei Tumori
Milan, Italy
Ospedale San Gerardo
Monza, Italy
Istituto Oncologico Veneto (IOV)
Padova, Italy
AO Arcispedale Santa Maria Nuova
Reggio Emilia, Italy
Policlinico Umberto I, Università di Roma "La Sapienza"
Roma, Italy
AO Ordine Mauriziano
Torino, Italy
AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna
Torino, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.